OncoMatch/Clinical Trials/NCT06179160
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Is NCT06179160 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments for solid tumors.
Treatment: INCB161734 · Cetuximab · Retifanlimab · GEMNabP · mFOLFIRINOX · FOLFOX · FOLFIRI · INCA33890 — This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Tumor Agnostic
Biomarker criteria
Required: KRAS g12d mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: kras g12d inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Hospital · Phoenix, Arizona
- Stanford University · Palo Alto, California
- UCLA Healthcare Hematology-Oncology · Santa Monica, California
- Sarah Cannon Research Institue At Healthone · Denver, Colorado
- Florida Cancer Specialists · Sarasota, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06179160 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior kras g12d inhibitor disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS g12d mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify